Completed INTERVENTIONAL 1-arm NCT03895034

Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes

A Single Center Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes

Sponsor: RxSight, Inc.

Conditions Aphakia Cataract

Interventions Light Adjustable lens (LAL) and Light Delivery Device (LDD)

Updated 7 times since 2019 Last updated: Apr 25, 2022 Started: Jun 14, 2018 Primary completion: Mar 1, 2020 Completion: Mar 1, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03895034, this observational or N/A phase trial focuses on Aphakia and Cataract and remains completed. Sponsored by RxSight, Inc., it has been updated 7 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jun 2022 — Jul 2024 [monthly]

Completed
Oct 2021 — Jun 2022 [monthly]

Completed

Status: Withheld → Completed
Jan 2021 — Oct 2021 [monthly]

Withheld

▶ Show 2 earlier versions

May 2020 — Jan 2021 [monthly]

Withheld
Apr 2019 — May 2020 [monthly]

Withheld

First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

RxSight, Inc.

Data source: RxSight, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tijuana, Mexico